Integer Holdings Corporation (ITGR) AI Stock Analysis

Integer Holdings Corporation is a medical device outsourcing manufacturer operating across the United States, Puerto Rico, Costa Rica, and internationally. The company operates through Medical and Non-Medical segments. Its Medical segment develops cardiac rhythm management devices such as pacemakers and implantable cardioverter defibrillators, neuromodulation products, batteries, device enclosures, and surgical instruments for orthopedic, arthroscopic, and general surgery procedures. Its Non-Medical segment provides customized battery power and management systems for energy, military, and environmental markets.

Integer generated a 5-year revenue CAGR of 11.5% between FY2020 and FY2025, with revenue climbing from $1.22B in FY2021 to $1.85B in FY2025. Over the same timeframe, gross margin contracted from 27.6% to 23.1%, while operating margin ended at 11.3% in FY2025. Net income was $102.8M in FY2025, down from $119.9M in FY2024, though diluted EPS rose to $6.41. For the trailing twelve months, revenue was $1.84B with a 7.0% profit margin. In the latest quarter ended June 30, 2026, quarterly revenue fell 2.6% year-over-year and quarterly earnings fell 33.7%.

As of June 30, 2026, Integer held $21.4M in cash and short-term investments against $1.36B in total debt, resulting in net debt of $1.34B. Total assets reached $3.42B against shareholders' equity of $1.72B, representing a debt-to-equity ratio of 0.79 and a current ratio of 3.73. In FY2025, operating cash flow was $196.1M, supporting capital expenditures of $91.0M and generating free cash flow of $105.1M. The company also allocated $50.0M to share buybacks in FY2025.

At $126.70, Integer trades at a trailing P/E of 34.6x, a forward P/E of 22.4x, and an EV/EBITDA of 18.4x. These multiples stand above the median of its US-listed Healthcare peers, which post a trailing P/E of 24.6x, forward P/E of 17.3x, and EV/EBITDA of 12.0x. However, its price-to-sales ratio of 2.3x sits below the peer median of 4.1x. Over the past year, Integer gained 22.9%, outperforming the S&P 500 (SPY) return of 16.8%, but its 5-year return of 41.9% lagged the index return of 83.0%.

All 9 analysts covering Integer rate the stock a Hold, with zero Buy or Sell ratings. The mean price target of $121.80 implies a 3.9% decline from the last closing price of $126.70. For the fiscal year ending December 31, 2026, consensus estimates anticipate revenue of $1.82B and EPS of $6.16, representing an EPS drop of 3.7%. Integer beat EPS expectations in each of the last 4 quarters, and its next earnings date is October 22, 2026.

This page is an AI-written research summary of Integer Holdings Corporation (ITGR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ITGR income statement, ITGR balance sheet, ITGR key metrics, ITGR analyst forecast, ITGR chart. See the ITGR stock overview for the latest quote and news.